The people-first approach transforming eClinical processes
Pharmaceutical Technology
NOVEMBER 7, 2024
With the boom in eClinical solutions showing no signs of slowing, adding a “human at the center” perspective can help optimize data management
Thu.Nov 07, 2024
130 
Sarepta scraps a Duchenne drug as gene therapy sales rise
Bio Pharma Dive
NOVEMBER 7, 2024
Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Now, Sarepta is abandoning a successor to its drug Exondys 51, citing an “evolving" treatment landscape.
Join 21,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
DBV Technologies’ stock slides as financial woes worsens
Pharmaceutical Technology
NOVEMBER 7, 2024
The company reported that it does not have sufficient cash reserves to operate for the next 12 months, can only fund operations into Q1 2025.
Moderna earnings beat forecasts, but analysts question whether sales spike will last
Bio Pharma Dive
NOVEMBER 7, 2024
Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients
Pharmaceutical Technology
NOVEMBER 7, 2024
The EMA has granted approval for Sanofi/Regeneron’s Dupixent (dupilumab) to treat EoE in children as young as one.
Inhibiting specific protein action could lead to precision therapy for some patients with drug-resistant leukemia
Medical Xpress
NOVEMBER 7, 2024
Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent among East Asians that contributes to drug resistance, driving the aggressive growth of cancer cells in patients with chronic myeloid leukemia.
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Grand Rounds November 1, 2024: Congenital Heart Initiative: Redefining Outcomes and Navigation to Adult Centered Care (CHI-RON) Study (Thomas W. Carton, PhD, MS; Anitha S. John, MD, PhD)
Rethinking Clinical Trials
NOVEMBER 7, 2024
Speakers Anitha S. John, MD, PhD Medical Director Washington Adult Congenital Heart Program Professor of Pediatrics Children’s National Hospital George Washington University Thomas W. Carton, PhD, MS Chief Data and Strategy Officer Louisiana Public Health Institute Slides Keywords Adult Congenital Heart Disease; Registry; Patient Engagement Key Points The research team reviewed the current challenges in adult congenital heart disease (ACHD) clinical
Q3 2024 update: artificial intelligence related private equity activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.
Biomarker identified for predicting inflammatory bowel disease treatment success
Medical Xpress
NOVEMBER 7, 2024
Not everyone responds equally well to treatments for inflammatory bowel disease (IBD). What will work for individual patients involves trial and error during the treatment process. Now, a team of researchers led by Charité—Universitätsmedizin, in collaboration with colleagues in Berlin and Bonn, has succeeded in identifying a biomarker that indicates whether or not treatment with a certain medication called an immunomodulator will be successful.
Q3 2024 update: artificial intelligence related private equity activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were three private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.
Webinar recap: Boosting recruitment and retention with SDOH data
pharmaphorum
NOVEMBER 7, 2024
Discover the key takeaways from a webinar focused on boosting recruitment and retention through Social Determinants of Health (SDOH) data. Learn how incorporating SDOH data can enhance your recruitment and retention strategies.
Q3 2024 update: COVID-19 related private equity activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $7.5m, according to GlobalData's Deals Database.
More turbulence at Aurinia as autoimmune drugmaker lays off 45% of workforce
Fierce Pharma
NOVEMBER 7, 2024
After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring. | After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting to restructuring, cutting the autoimmune disease biotech's workforce for a second time in less than a year.
Q3 2024 update: COVID-19 related private equity activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $7.5m, according to GlobalData's Deals Database.
The New Age of Decentralized Clinical Trials
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Novo sheds kidney drug licensed for $1.3bn a year ago
pharmaphorum
NOVEMBER 7, 2024
Novo Nordisk has abandoned a drug it licensed from KBP Biosciences last year in a deal valued at up to $1.3 billion after it missed the mark in a chronic kidney disease (CKD) trial.The Danish group bought rights to ocedurenone, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA), from the Singapore biotech in October 2023 as a companion to its GLP-1-based therapies for reducing cardiovascular risk and kidney disease in people with diabetes and obesity.
Private equity deals in pharmaceutical in Canada remained flat in Q3 2024
Pharmaceutical Technology
NOVEMBER 7, 2024
In Canada pharmaceutical industry, there were two private equity deals announced in Q3 2024, worth a total value of $4.2m, according to GlobalData's Deals Database.
'Radar stethoscope' could improve contactless health monitoring technology
Medical Xpress
NOVEMBER 7, 2024
A new advance in health monitoring which uses radar to "listen" to patients' heart sounds with remarkable accuracy could lead to a new generation of contactless medical monitoring equipment.
Leading sales and marketing intent data, database and data enrichment providers and technology solutions for the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
Discover the top sales and marketing intelligence providers for the pharmaceutical industry, offering predictive insights and data enrichment to drive growth.
Artificial sensory cilia can monitor internal biomarkers to detect and assess airway diseases
Medical Xpress
NOVEMBER 7, 2024
Xiaoguang Dong, assistant professor of mechanical engineering at Vanderbilt University, is leading a team of researchers that has developed a system of artificial cilia capable of monitoring mucus conditions in human airways to better detect infection, airway obstruction, or the severity of diseases like cystic fibrosis (CF), chronic obstructive pulmonary diseases (COPD) and lung cancer.
Santen, Arctic Vision sign deal for ARVN001 to treat UME
Pharmaceutical Technology
NOVEMBER 7, 2024
Santen Pharmaceutical and Arctic Vision have signed a commercial collaboration agreement for the ARVN001to treat uveitic macular oedema.
About one in five adults experienced anxiety, depression in 2022
Medical Xpress
NOVEMBER 7, 2024
About one in five adults experienced any symptoms of anxiety and symptoms of depression during 2022, according to a study published online Nov. 7 in the National Health Statistics Reports, a publication from the National Center for Health Statistics.
GHO and Ampersand Capital to acquire Avid Bioservices
Pharmaceutical Technology
NOVEMBER 7, 2024
Funds managed by GHO Capital Partners and Ampersand Capital Partners have signed a definitive agreement to acquire Avid Bioservices.
The New Age of Decentralized Clinical Trials
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Researchers are one step closer to developing cell-based therapy for hypothyroidism
Medical Xpress
NOVEMBER 7, 2024
Researchers from the Center for Regenerative Medicine (CReM) and the Department of Medicine at Boston Medical Center (BMC) and Boston University (BU) have made a breakthrough that holds promise for developing new therapies to treat hypothyroidism, a condition where the thyroid gland does not produce enough hormones. The research team, led by Darrell Kotton, MD, and Anthony Hollenberg, MD, has developed a successful protocol for producing mature thyroid follicular epithelial cells (TFCs), which a
Vidac secures funding to advance skin cancer trials of novel ointment
Pharmaceutical Technology
NOVEMBER 7, 2024
Vidac will use the new funds to initiate a Phase IIb trial of its lead candidate VDA-1102 in patients with actinic keratosis.
Journey Medical’s Emrosi Wins FDA Approval for Rosacea, Could Rival Galderma’s Oracea
XTalks
NOVEMBER 7, 2024
Journey Medical Corporation, a leading biopharmaceutical company dedicated to the development and commercialization of innovative dermatology treatments, has announced that the US Food and Drug Administration (FDA) has approved Emrosi (minocycline hydrochloride extended release capsules, 40 mg), formerly referred to as DFD-29, for the treatment of rosacea.
Q3 2024 update: ecommerce related M&A activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.
Unlocking Excellence: How Catalent Is Transforming Japan’s Clinical Research
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Fierce Pharma
NOVEMBER 7, 2024
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its bread-and-butter antirival franchise with an eye on the potential of its long-acting | Gilead's CAR-T therapies Yescarta and Tecartus have stayed relatively flat all year with its Yescarta facing a 1% decline over the third quarter due to competition.
Q3 2024 update: ecommerce related M&A activity in the pharmaceutical industry
Pharmaceutical Technology
NOVEMBER 7, 2024
In the global pharmaceutical industry, there were eight M&A deals announced in Q3 2024, worth a total value of $1.3bn, according to GlobalData's Deals Database.
Mitochondrial dynamics provide clues for halting the metastatic progression of breast cancer
Medical Xpress
NOVEMBER 7, 2024
Mitochondria have long been known as the tiny organelles that act as the battery packs inside our cells while also serving as internal sensors and communicators. But relatively little is understood about how their energy-producing activities in soupy cellular interiors impacts metastatic cancer, which occurs when cancerous cells spread in the body.
Blueprint's mastocytosis drug Ayvakit cleared for NHS use
pharmaphorum
NOVEMBER 7, 2024
NICE has recommended broad use of Blueprint Medicines' recently-approved therapy for rare blood disorder advanced systemic mastocytosis
How Machine Learning Drives Clinical Trial Efficiency
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Let's personalize your content